| $385M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $91M |
Buys | $52,640,518 | 2 | 8 |
Sells | $17,821,378 | 22 | 92 |
| George Simeon | director | 1 | $51.5M | 0 | $0 | $51.5M |
| Treco Douglas A | director | 1 | $1.14M | 0 | $0 | $1.14M |
| Patel Naimish | Chief Medical Officer | 0 | $0 | 2 | $362,596 | $-362,596 |
| KASINGER JAMES R. | General Counsel and Secretary | 0 | $0 | 5 | $645,902 | $-645,902 |
| Prasad Raju | Chief Financial Officer | 0 | $0 | 6 | $5.3M | $-5.3M |
| Kulkarni Samarth | Chief Executive Officer | 0 | $0 | 9 | $11.52M | $-11.52M |
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Over the last 12 months, insiders at CRISPR Therapeutics AG have bought $52.64M and sold $17.82M worth of CRISPR Therapeutics AG stock.
On average, over the past 5 years, insiders at CRISPR Therapeutics AG have bought $26.5M and sold $17.5M worth of stock each year.
Highest buying activity among insiders over the last 12 months: George Simeon (director) — $51.5M. Treco Douglas A (director) — $1.14M.
The last purchase of 20,000 shares for transaction amount of $1.14M was made by Treco Douglas A (director) on 2025‑08‑06.
| 2026-05-29 | Sale | Patel Naimish | Chief Medical Officer | 3,786 0.0039% | $55.62 | $210,577 | -4.11% | |
| 2026-03-23 | Sale | Kulkarni Samarth | Chief Executive Officer | 10,020 0.0104% | $46.78 | $468,736 | +11.05% | |
| 2026-03-23 | Sale | KASINGER JAMES R. | General Counsel and Secretary | 3,182 0.0033% | $46.78 | $148,854 | +11.05% | |
| 2026-03-23 | Sale | Prasad Raju | Chief Financial Officer | 3,708 0.0039% | $46.78 | $173,460 | +11.05% | |
| 2026-03-16 | Sale | Kulkarni Samarth | Chief Executive Officer | 10,349 0.0107% | $48.26 | $499,443 | +6.72% | |
| 2026-03-16 | Sale | KASINGER JAMES R. | General Counsel and Secretary | 3,450 0.0036% | $48.26 | $166,497 | +6.72% | |
| 2026-03-16 | Sale | Prasad Raju | Chief Financial Officer | 9,869 0.0102% | $48.26 | $476,278 | +6.72% | |
| 2026-03-16 | Sale | Patel Naimish | Chief Medical Officer | 3,150 0.0033% | $48.26 | $152,019 | +6.72% | |
| 2026-03-11 | Sale | Kulkarni Samarth | Chief Executive Officer | 9,798 0.0108% | $52.80 | $517,334 | +3.02% | |
| 2026-03-11 | Sale | KASINGER JAMES R. | General Counsel and Secretary | 2,800 0.0031% | $52.80 | $147,840 | +3.02% | |
| 2026-02-19 | Sale | Kulkarni Samarth | Chief Executive Officer | 6,967 0.0071% | $52.58 | $366,325 | -4.21% | |
| 2026-02-19 | Sale | KASINGER JAMES R. | General Counsel and Secretary | 2,112 0.0022% | $52.58 | $111,049 | -4.21% | |
| 2026-01-22 | Sale | Kulkarni Samarth | Chief Executive Officer | 60,000 0.0624% | $60.23 | $3.61M | -14.15% | |
| 2026-01-22 | Sale | Prasad Raju | Chief Financial Officer | 34,972 0.0363% | $60.19 | $2.1M | -14.15% | |
| 2026-01-20 | Sale | Kulkarni Samarth | Chief Executive Officer | 30,000 0.031% | $51.75 | $1.55M | -0.48% | |
| 2026-01-06 | Sale | Prasad Raju | Chief Financial Officer | 29,700 0.037% | $60.16 | $1.79M | -9.35% | |
| 2025-12-22 | Sale | Prasad Raju | Chief Financial Officer | 3,528 0.0038% | $55.10 | $194,401 | -8.56% | |
| 2025-12-22 | Sale | Prasad Raju | Chief Financial Officer | 10,000 0.011% | $55.95 | $559,549 | -8.56% | |
| 2025-10-17 | Sale | Kulkarni Samarth | Chief Executive Officer | 50,895 0.055% | $67.91 | $3.46M | -22.36% | |
| 2025-10-14 | Sale | Kulkarni Samarth | Chief Executive Officer | 4,242 0.0045% | $66.60 | $282,517 | -22.45% |
| George Simeon | director | 1730179 1.7939% | $89.69M | 2 | 0 | +31.44% |
| Kulkarni Samarth | Chief Executive Officer | 255501 0.2649% | $13.25M | 0 | 58 | |
| KASINGER JAMES R. | General Counsel and Secretary | 94308 0.0978% | $4.89M | 0 | 15 | |
| Treco Douglas A | director | 22000 0.0228% | $1.14M | 1 | 0 | |
| Patel Naimish | Chief Medical Officer | 19357 0.0201% | $1M | 1 | 3 | +64.51% |
| Prasad Raju | Chief Financial Officer | 15565 0.0161% | $806,889.60 | 0 | 9 | |
| BAYER AKTIENGESELLSCHAFT | 10 percent owner | 5632802 5.8402% | $292M | 1 | 0 | +77.06% |
| Vertex Pharmaceuticals (Europe) Ltd | 10 percent owner | 5380940 5.5791% | $278.95M | 4 | 0 | +63.29% |
| CELGENE CORP /DE/ | 10 percent owner | 4173019 4.3267% | $216.33M | 1 | 21 | +31.44% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 3220627 3.3392% | $166.96M | 1 | 0 | +31.44% |
| EMSTER KURT VON | director | 1171268 1.2144% | $60.72M | 2 | 39 | +54.25% |
| Woiwode Thomas | director | 640014 0.6636% | $33.18M | 1 | 11 | +31.44% |
| Novak Rodger | President | 573007 0.5941% | $29.7M | 0 | 41 | |
| Lundberg Sven Ante | Chief Scientific Officer | 505617 0.5242% | $26.21M | 1 | 0 | +31.44% |
| Bolzon Bradley J PhD | director | 148831 0.1543% | $7.72M | 1 | 30 | +31.44% |
| Versant Venture Capital IV, L.P. | 10 percent owner | 45171 0.0468% | $2.34M | 1 | 1 | +31.44% |
| Versant Venture Capital V, L.P. | 10 percent owner | 44582 0.0462% | $2.31M | 0 | 1 | |
| Ho Tony W | Executive VP, Head of R&D | 33964 0.0352% | $1.76M | 0 | 5 | |
| Dylan-Hyde Tyler | Chief Legal Officer | 25204 0.0261% | $1.31M | 0 | 18 | |
| Bruno Julianne | Chief Operating Officer | 10544 0.0109% | $546,600.96 | 0 | 5 | |
| Greene John | director | 7000 0.0073% | $362,880.00 | 1 | 0 | +20.43% |
| TOMSICEK MICHAEL JOHN | Chief Financial Officer | 1891 0.002% | $98,029.44 | 0 | 3 | |
| Klein Lawrence Otto | CBO & COO | 1050 0.0011% | $54,432.00 | 0 | 7 | |
| CAGNONI PABLO J | director | 0 0% | $0 | 0 | 5 |
$67,892,722 | 138 | 28.28% | $4.75B | |
$11,588,217 | 69 | 42.07% | $3.83B | |
$224,662,742 | 52 | 32.03% | $4.69B | |
$11,583,737 | 45 | 49.75% | $4.26B | |
$104,428,685 | 44 | 22.55% | $5.5B | |
$5,066,938 | 27 | 26.38% | $4.08B | |
$150,253,463 | 26 | -52.83% | $6.13B | |
$103,944,213 | 17 | 5.95% | $5.93B | |
CRISPR Therapeutics AG (CRSP) | $74,969,332 | 16 | 46.49% | $5B |
$112,580,865 | 16 | 0.64% | $3.83B | |
$75,296,863 | 13 | 33.79% | $6.1B | |
$57,686,748 | 13 | 21.11% | $5.89B | |
$9,976,473 | 12 | 29.52% | $5.37B | |
$3,073,199 | 10 | 16.77% | $4.31B | |
$20,831,864 | 10 | 69.29% | $5.3B | |
$1,248,715 | 10 | 5.66% | $3.89B | |
$25,064,843 | 9 | 12.75% | $5.31B | |
$50,990,767 | 2 | 19.79% | $5.38B | |
$7,600,000 | 1 | -4.05% | $4.74B |
| Increased Positions | 249 | +52.42% | 9M | +11.91% |
| Decreased Positions | 183 | -38.53% | 5M | -6.67% |
| New Positions | 94 | New | 5M | New |
| Sold Out Positions | 54 | Sold Out | 871,559 | Sold Out |
| Total Postitions | 541 | +13.89% | 76M | +5.24% |
| Ark Investment Management Llc | $526,246.00 | 10.3% | 9.79M | -395,617 | -3.88% | 2025-09-30 |
| Blackrock, Inc. | $379,086.00 | 7.42% | 7.05M | +983,787 | +16.22% | 2025-09-30 |
| Capital International Investors | $303,761.00 | 5.95% | 5.65M | +55,511 | +0.99% | 2025-09-30 |
| Orbis Allan Gray Ltd | $267,887.00 | 5.24% | 4.98M | +2M | +80.21% | 2025-09-30 |
| State Street Corp | $215,469.00 | 4.22% | 4.01M | +736,637 | +22.52% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $176,505.00 | 3.46% | 3.28M | -400,442 | -10.87% | 2025-09-30 |
| Vanguard Group Inc | $127,147.00 | 2.49% | 2.36M | +66,556 | +2.9% | 2025-09-30 |
| Ubs Group Ag | $125,771.00 | 2.46% | 2.34M | -504,521 | -17.74% | 2025-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | $116,341.00 | 2.28% | 2.16M | -251,163 | -10.4% | 2025-09-30 |
| Amova Asset Management Americas, Inc. | $116,341.00 | 2.28% | 2.16M | -250,596 | -10.38% | 2025-09-30 |